Geode Capital Management LLC Has $27.33 Million Stock Holdings in Pacira BioSciences, Inc. $PCRX

Geode Capital Management LLC increased its holdings in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX) by 0.5% during the 2nd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,143,190 shares of the company’s stock after acquiring an additional 5,658 shares during the period. Geode Capital Management LLC owned about 2.54% of Pacira BioSciences worth $27,326,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in PCRX. Caitong International Asset Management Co. Ltd bought a new position in Pacira BioSciences during the first quarter worth about $51,000. US Bancorp DE grew its stake in shares of Pacira BioSciences by 31.0% in the 1st quarter. US Bancorp DE now owns 2,270 shares of the company’s stock valued at $56,000 after purchasing an additional 537 shares during the period. Brooklyn Investment Group raised its holdings in shares of Pacira BioSciences by 372.2% in the 1st quarter. Brooklyn Investment Group now owns 2,238 shares of the company’s stock worth $56,000 after buying an additional 1,764 shares in the last quarter. Wealthquest Corp bought a new position in shares of Pacira BioSciences during the 1st quarter worth approximately $59,000. Finally, Strs Ohio bought a new position in shares of Pacira BioSciences during the 1st quarter worth approximately $75,000. Institutional investors own 99.73% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have weighed in on the company. Zacks Research upgraded Pacira BioSciences from a “strong sell” rating to a “hold” rating in a research report on Thursday, August 14th. Truist Financial reduced their target price on shares of Pacira BioSciences from $30.00 to $28.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. HC Wainwright reaffirmed a “buy” rating and issued a $38.00 target price on shares of Pacira BioSciences in a report on Monday, November 17th. Weiss Ratings reissued a “sell (d+)” rating on shares of Pacira BioSciences in a report on Monday. Finally, Wall Street Zen upgraded shares of Pacira BioSciences from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 8th. Four investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold” and a consensus price target of $27.60.

Pacira BioSciences Price Performance

Shares of PCRX stock opened at $23.57 on Friday. Pacira BioSciences, Inc. has a 52 week low of $16.41 and a 52 week high of $27.64. The stock has a market capitalization of $1.01 billion, a PE ratio of -8.48 and a beta of 0.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.91 and a current ratio of 2.38. The stock’s fifty day moving average is $23.32 and its 200-day moving average is $24.22.

Pacira BioSciences (NASDAQ:PCRX) last issued its quarterly earnings results on Thursday, November 6th. The company reported $0.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.65 by $0.05. Pacira BioSciences had a negative net margin of 18.08% and a positive return on equity of 13.29%. The business had revenue of $179.52 million for the quarter, compared to the consensus estimate of $182.86 million. During the same quarter in the prior year, the company earned $0.79 EPS. The firm’s quarterly revenue was up 6.5% on a year-over-year basis. Pacira BioSciences has set its FY 2025 guidance at EPS. Equities research analysts expect that Pacira BioSciences, Inc. will post 2.41 EPS for the current fiscal year.

Insider Activity at Pacira BioSciences

In other news, insider Jonathan Slonin sold 3,960 shares of the stock in a transaction that occurred on Monday, November 17th. The shares were sold at an average price of $24.09, for a total transaction of $95,396.40. Following the sale, the insider directly owned 178,367 shares of the company’s stock, valued at $4,296,861.03. This represents a 2.17% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 6.40% of the stock is owned by company insiders.

Pacira BioSciences Profile

Pacira Biosciences, Inc is a holding company, which engages in the provision of non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. Its products include EXPAREL, iovera, and DepoFoam. The company was founded in December 2006 and is headquartered in Tampa, FL.